RESUMEN
The active modulation of the Fano resonance is rare but desirable. However, recent studies mostly focused on a single modulation method and few reported the use of three photoelectric control methods. A tunable graphene DNA-like metamaterial modulator with multispectral Fano resonance is demonstrated. In experimentally fabricated metamaterials with six photoelectric joint modulation patterns, each joint shows different optoelectrical response characteristics. Ultrahigh modulation depth (MD) up to 982% was achieved at 1.5734 THz with a 1.040 A external laser pump by involving combined optoelectrical methods. These results show that the metasurface modulator is a promising platform for higher-order Fano resonance modulation and communication fields.
Asunto(s)
Grafito , ADN , LuzRESUMEN
The phenomenon of multi-resonant Fano resonances is important for the design of biosensors and communication fields. There are very few studies reporting the multi-band Fano resonance metamaterials with more than three resonance frequencies, or the tunable optical metamaterials to control the multi-band Fano resonance characteristics. Here, we report dual control of multi-band Fano resonances with a metal-halide perovskite-integrated terahertz metasurface by lasers and an electrical field. By tuning the conductivity of the perovskite film on the metasurface, ultrasensitive optoelectronic modulation was achieved. The terahertz transmission amplitude exhibited increasing and decreasing stages. We analyzed the physical phenomena and found that capacitance effects and Fermi-level enhancement had significant roles in the optical- and electronic-modulation experiments. The resonant frequencies in the electronic modulation had broader frequency shifts and a higher and wider tunable modulation depth range. More importantly, the maximum modulation depth was as high as 197%, with a significant fluctuation in the amplitude and more unstable frequency shifts in the transmission spectra.
RESUMEN
Bromodomain and extra-terminal domain (BET) family proteins are promising anticancer targets. Most BET inhibitors in clinical trials are monovalent. They competitively bind to one of the bromodomains (BD1 and BD2) in BET proteins and exhibit relatively weak anticancer activity, poor pharmacokinetics, and low metabolic stability. Here, we evaluated the anticancer activity of a novel bivalent BET inhibitor, N2817, which consists of two molecules of the monovalent BET inhibitor 8124-053 connected by a common piperazine ring, rendering a long linker unnecessary. Compared with ABBV-075, one of the potent monovalent BET inhibitors reported to date, N2817 showed greater potency in inhibiting proliferation, arresting cell-cycle, inducing apoptosis, and suppressing the growth of tumor xenografts. Moreover, N2817 showed high metabolic stability, a relatively long half-life, and no brain penetration after oral administration. Additionally, N2817 directly bound and inhibited another BD-containing protein, TAF1 (BD2), as evidenced by a reduction in mRNA and protein levels. TAF1 inhibition contributed to the anticancer effect of N2817. Therefore, this study offers a new paradigm for designing bivalent BET inhibitors and introduces a novel potent bivalent BET inhibitor and a new anticancer mechanism.